Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Net loss	$ (46,847)	$ (51,878)
Adjustments to reconcile net loss to net cash used in operations:
Share-based compensation	14,972	24,948
Depreciation and amortization	2,582	5,345
Amortization of right-of-use assets	1,542	1,975
Loss on impairment of long lived assets	0	186
Write-down of escrow receivable	1,081	0
Loss contingency	1,168	0
Allowance for doubtful accounts	291	250
Change in fair value of warrant liabilities	(79)	(7,659)
Change in fair value of contingent consideration	(211)	0
Other	2	(10)
Changes in operating assets and liabilities:
Accounts receivable	(4,752)	(1,139)
Prepaid expenses and other assets	465	(2,179)
Accounts payable	125	(58)
Accrued expenses and other liabilities	(1,018)	(931)
Accrued compensation and benefits	1,443	302
Operating lease liabilities	(2,723)	(1,785)
Net cash used in operating activities	(31,959)	(32,633)
Cash flows from investing activities:
Acquisition of Accuidity, net of cash acquired	(9,207)	0
Maturity of investments and term deposits	32,711	6,559
Purchases of investments and term deposits	(60,266)	0
Purchases of property and equipment	(198)	(792)
Capitalized internal-use software development costs	0	(48)
Net cash (used in) provided by investing activities	(36,960)	5,719
Cash flows from financing activities:
Proceeds from exercise of options	160	473
Taxes withheld and paid related to net share settlement of equity awards	(1,061)	(3,843)
Share buyback	(4,139)	0
Cash paid for fractional shares related to stock split	(4)	0
Net cash used in financing activities	(5,044)	(3,370)
Effect of changes in currency exchange rates on cash and cash equivalents	1,151	57
Net decrease in cash and cash equivalents	(72,812)	(30,227)
Cash, cash equivalents and restricted cash, beginning of the period	106,256	145,784
Cash, cash equivalents and restricted cash, end of the period	33,444	115,557
Reconciliation of cash, cash equivalents and restricted cash to the amounts reported within the consolidated balance sheets
Cash and cash equivalents	32,294	114,454
Restricted cash	1,150	1,103
Total cash, cash equivalents and restricted cash, end of the period	33,444	115,557
Supplemental disclosures of cash flow information:
Cash paid for taxes	669	519
Supplemental disclosure of non-cash investing and financing activities:
Lease liabilities arising from obtaining right-of-use assets	102	4,506
Vesting of early exercised stock options and restricted stock awards	51	107
Capitalized internal-use software development costs accrued and not yet paid	0	117
Common stock issued in connection with Accuidity acquisition	0	15,375
Contingent consideration in connection with Accuidity acquisition	$ 6,023	$ 0